Beam Therapeutics (NASDAQ:BEAM) Shares Gap Up on Better-Than-Expected Earnings

Beam Therapeutics Inc. (NASDAQ:BEAM)’s stock price gapped up prior to trading on Tuesday after the company announced better than expected quarterly earnings. The stock had previously closed at $28.33, but opened at $29.75. Beam Therapeutics shares last traded at $30.0010, with a volume of 619,040 shares traded.

The company reported $2.33 EPS for the quarter, beating the consensus estimate of ($1.13) by $3.46. The company had revenue of $114.11 million for the quarter, compared to the consensus estimate of $13.22 million. Beam Therapeutics had a negative return on equity of 42.86% and a negative net margin of 744.41%.The company’s revenue for the quarter was up 280.3% compared to the same quarter last year. During the same quarter last year, the company posted ($1.09) earnings per share.

Trending Headlines about Beam Therapeutics

Here are the key news stories impacting Beam Therapeutics this week:

• Positive Sentiment: Quarterly results materially beat expectations — Zacks reports a Q4 loss of $0.10 per share versus a consensus loss of $1.13, and the company’s published results / MarketBeat summary show revenue of $114.1M (vs. roughly $13M expected) and year-over-year revenue growth of ~280%, a major upside driver for the stock. Zacks: BEAM Q4 Results MarketBeat: BEAM Earnings
• Positive Sentiment: Announced a $500 million strategic financing facility with Sixth Street — $100M funded at close, up to $400M available, seven‑year term, described as long-term non-dilutive capital to support a potential launch of ristoglogene autogetemcel (risto-cel) in sickle cell disease. This materially strengthens the balance sheet ahead of commercialization planning. GlobeNewswire: Financing
• Positive Sentiment: Launched a new liver‑targeted genetic disease program in phenylketonuria (PKU) with an IND for BEAM‑304 anticipated in 2026 — expands the company’s base‑editing pipeline and potential long‑term value creation. GlobeNewswire: PKU Program
• Positive Sentiment: Analysts turned more constructive — Canaccord issued a Buy and brokers’ consensus reads as a “Moderate Buy,” which can increase demand from institutional and retail investors. Analyst: Canaccord Buy Analyst Consensus
• Neutral Sentiment: Company hosted an investor webcast to present Q4/2025 results and the new liver program — useful for additional color and management guidance, but the webcast itself is informational rather than a direct catalyst. GlobeNewswire: Webcast Notice
• Negative Sentiment: Despite the beats, the company still shows negative profitability metrics (large negative net margin and negative return on equity) and consensus forecasts expect negative EPS for the current fiscal year — risks remain around sustainable profitability and execution toward commercialization. MarketBeat: Profitability Notes

Analyst Ratings Changes

BEAM has been the topic of several recent research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Beam Therapeutics in a report on Wednesday, January 21st. Wall Street Zen cut Beam Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, February 8th. Evercore initiated coverage on shares of Beam Therapeutics in a research note on Monday, November 24th. They set an “outperform” rating and a $35.00 price objective on the stock. UBS Group began coverage on Beam Therapeutics in a report on Wednesday, January 7th. They issued a “neutral” rating and a $28.00 price target for the company. Finally, Benchmark restated a “speculative buy” rating on shares of Beam Therapeutics in a report on Monday, November 17th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Beam Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $45.69.

Insider Buying and Selling

In related news, insider Christine Bellon sold 18,629 shares of the stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $34.61, for a total value of $644,749.69. Following the completion of the transaction, the insider owned 97,038 shares of the company’s stock, valued at $3,358,485.18. This represents a 16.11% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 3.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Beam Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in BEAM. Bank Julius Baer & Co. Ltd Zurich purchased a new position in Beam Therapeutics in the fourth quarter worth $47,000. Larson Financial Group LLC raised its stake in shares of Beam Therapeutics by 4,370.5% during the 3rd quarter. Larson Financial Group LLC now owns 1,967 shares of the company’s stock worth $48,000 after purchasing an additional 1,923 shares during the period. Kestra Advisory Services LLC purchased a new position in shares of Beam Therapeutics in the 4th quarter worth about $59,000. Van ECK Associates Corp grew its position in Beam Therapeutics by 48.7% during the third quarter. Van ECK Associates Corp now owns 2,158 shares of the company’s stock valued at $52,000 after buying an additional 707 shares during the period. Finally, Leonteq Securities AG purchased a new stake in Beam Therapeutics during the fourth quarter worth about $66,000. Institutional investors and hedge funds own 99.68% of the company’s stock.

Beam Therapeutics Price Performance

The firm has a market cap of $3.28 billion, a PE ratio of -7.29 and a beta of 2.12. The business’s fifty day moving average is $28.74 and its 200-day moving average is $24.99.

About Beam Therapeutics

Beam Therapeutics, Inc (NASDAQ: BEAM) is a biotechnology company dedicated to developing precision genetic medicines through its pioneering base editing platform. Headquartered in Cambridge, Massachusetts, with additional research facilities in Philadelphia, the company focuses on engineering molecular editors capable of making precise single-nucleotide changes in DNA. By harnessing its proprietary base editing technology, Beam aims to correct or disrupt disease-causing genetic variants at their source, offering the potential for novel therapies in areas with significant unmet medical need.

Founded in 2017 as a spin-out from Harvard University and the Broad and Whitehead Institutes, Beam was co-founded by leading academic researcher David R.